nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—CYP2D6—Hydroxyurea—head and neck cancer	0.123	0.739	CbGbCtD
Zuclopenthixol—DRD5—eyelid—head and neck cancer	0.0979	0.393	CbGeAlD
Zuclopenthixol—CYP2D6—Vinblastine—head and neck cancer	0.0435	0.261	CbGbCtD
Zuclopenthixol—HRH1—nose—head and neck cancer	0.0324	0.13	CbGeAlD
Zuclopenthixol—Ileus paralytic—Vinblastine—head and neck cancer	0.025	0.0428	CcSEcCtD
Zuclopenthixol—HTR2A—trigeminal nerve—head and neck cancer	0.0213	0.0854	CbGeAlD
Zuclopenthixol—Parkinsonism—Fluorouracil—head and neck cancer	0.0156	0.0267	CcSEcCtD
Zuclopenthixol—HTR2A—cranial nerve—head and neck cancer	0.0152	0.0608	CbGeAlD
Zuclopenthixol—Sudden death—Fluorouracil—head and neck cancer	0.0139	0.0237	CcSEcCtD
Zuclopenthixol—Amenorrhoea—Hydroxyurea—head and neck cancer	0.0112	0.0192	CcSEcCtD
Zuclopenthixol—Menstruation irregular—Docetaxel—head and neck cancer	0.00926	0.0158	CcSEcCtD
Zuclopenthixol—Speech disorder—Fluorouracil—head and neck cancer	0.00826	0.0141	CcSEcCtD
Zuclopenthixol—DRD5—lymphoid tissue—head and neck cancer	0.00768	0.0308	CbGeAlD
Zuclopenthixol—Breast disorder—Hydroxyurea—head and neck cancer	0.00647	0.0111	CcSEcCtD
Zuclopenthixol—Pancytopenia—Vinblastine—head and neck cancer	0.00645	0.011	CcSEcCtD
Zuclopenthixol—HTR6—head—head and neck cancer	0.00635	0.0255	CbGeAlD
Zuclopenthixol—Rhinorrhoea—Docetaxel—head and neck cancer	0.00633	0.0108	CcSEcCtD
Zuclopenthixol—DRD5—head—head and neck cancer	0.00619	0.0248	CbGeAlD
Zuclopenthixol—Pancytopenia—Hydroxyurea—head and neck cancer	0.00588	0.0101	CcSEcCtD
Zuclopenthixol—Amenorrhoea—Docetaxel—head and neck cancer	0.00583	0.00998	CcSEcCtD
Zuclopenthixol—Dysuria—Hydroxyurea—head and neck cancer	0.00579	0.0099	CcSEcCtD
Zuclopenthixol—Neutropenia—Hydroxyurea—head and neck cancer	0.00579	0.0099	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Vinblastine—head and neck cancer	0.00565	0.00966	CcSEcCtD
Zuclopenthixol—Weight increased—Hydroxyurea—head and neck cancer	0.00563	0.00964	CcSEcCtD
Zuclopenthixol—Drowsiness—Hydroxyurea—head and neck cancer	0.00552	0.00944	CcSEcCtD
Zuclopenthixol—Amnesia—Fluorouracil—head and neck cancer	0.00549	0.00939	CcSEcCtD
Zuclopenthixol—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00542	0.00927	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00522	0.00893	CcSEcCtD
Zuclopenthixol—Injection site reaction—Docetaxel—head and neck cancer	0.0051	0.00872	CcSEcCtD
Zuclopenthixol—Ataxia—Fluorouracil—head and neck cancer	0.00485	0.00829	CcSEcCtD
Zuclopenthixol—DRD1—head—head and neck cancer	0.00473	0.019	CbGeAlD
Zuclopenthixol—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00461	0.00789	CcSEcCtD
Zuclopenthixol—ADRA1A—epithelium—head and neck cancer	0.00459	0.0184	CbGeAlD
Zuclopenthixol—Angiopathy—Hydroxyurea—head and neck cancer	0.0045	0.00769	CcSEcCtD
Zuclopenthixol—Eosinophilia—Fluorouracil—head and neck cancer	0.00441	0.00755	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Vinblastine—head and neck cancer	0.00439	0.00751	CcSEcCtD
Zuclopenthixol—HTR2A—neck—head and neck cancer	0.00436	0.0175	CbGeAlD
Zuclopenthixol—Erythema—Hydroxyurea—head and neck cancer	0.00431	0.00738	CcSEcCtD
Zuclopenthixol—Malaise—Vinblastine—head and neck cancer	0.00427	0.0073	CcSEcCtD
Zuclopenthixol—Vertigo—Vinblastine—head and neck cancer	0.00425	0.00727	CcSEcCtD
Zuclopenthixol—Leukopenia—Vinblastine—head and neck cancer	0.00423	0.00724	CcSEcCtD
Zuclopenthixol—Pancytopenia—Fluorouracil—head and neck cancer	0.00423	0.00724	CcSEcCtD
Zuclopenthixol—Convulsion—Vinblastine—head and neck cancer	0.0041	0.00701	CcSEcCtD
Zuclopenthixol—Hypertension—Vinblastine—head and neck cancer	0.00408	0.00699	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00407	0.00696	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.004	0.00685	CcSEcCtD
Zuclopenthixol—Discomfort—Vinblastine—head and neck cancer	0.00398	0.00681	CcSEcCtD
Zuclopenthixol—Hot flush—Docetaxel—head and neck cancer	0.00398	0.0068	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Docetaxel—head and neck cancer	0.00394	0.00675	CcSEcCtD
Zuclopenthixol—Malaise—Hydroxyurea—head and neck cancer	0.00389	0.00665	CcSEcCtD
Zuclopenthixol—Leukopenia—Hydroxyurea—head and neck cancer	0.00386	0.0066	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Vinblastine—head and neck cancer	0.00378	0.00647	CcSEcCtD
Zuclopenthixol—HRH1—connective tissue—head and neck cancer	0.00374	0.015	CbGeAlD
Zuclopenthixol—Convulsion—Hydroxyurea—head and neck cancer	0.00374	0.00639	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Fluorouracil—head and neck cancer	0.00371	0.00634	CcSEcCtD
Zuclopenthixol—Anorexia—Vinblastine—head and neck cancer	0.00368	0.00629	CcSEcCtD
Zuclopenthixol—ADRA2A—connective tissue—head and neck cancer	0.00368	0.0148	CbGeAlD
Zuclopenthixol—Migraine—Docetaxel—head and neck cancer	0.00366	0.00627	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00365	0.00624	CcSEcCtD
Zuclopenthixol—Discomfort—Hydroxyurea—head and neck cancer	0.00363	0.00621	CcSEcCtD
Zuclopenthixol—HRH1—epithelium—head and neck cancer	0.00355	0.0143	CbGeAlD
Zuclopenthixol—ADRA1A—lymphoid tissue—head and neck cancer	0.00354	0.0142	CbGeAlD
Zuclopenthixol—Ataxia—Docetaxel—head and neck cancer	0.0035	0.00599	CcSEcCtD
Zuclopenthixol—Paraesthesia—Vinblastine—head and neck cancer	0.00347	0.00593	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00345	0.00591	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00345	0.0059	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Docetaxel—head and neck cancer	0.00344	0.00588	CcSEcCtD
Zuclopenthixol—Skin disorder—Hydroxyurea—head and neck cancer	0.00342	0.00585	CcSEcCtD
Zuclopenthixol—Breast disorder—Docetaxel—head and neck cancer	0.00336	0.00575	CcSEcCtD
Zuclopenthixol—Anorexia—Hydroxyurea—head and neck cancer	0.00336	0.00574	CcSEcCtD
Zuclopenthixol—Decreased appetite—Vinblastine—head and neck cancer	0.00336	0.00574	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Docetaxel—head and neck cancer	0.00333	0.00569	CcSEcCtD
Zuclopenthixol—Constipation—Vinblastine—head and neck cancer	0.0033	0.00565	CcSEcCtD
Zuclopenthixol—Pain—Vinblastine—head and neck cancer	0.0033	0.00565	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00328	0.00561	CcSEcCtD
Zuclopenthixol—Arrhythmia—Fluorouracil—head and neck cancer	0.00319	0.00545	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Vinblastine—head and neck cancer	0.00318	0.00544	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00316	0.0054	CcSEcCtD
Zuclopenthixol—HRH1—trachea—head and neck cancer	0.00314	0.0126	CbGeAlD
Zuclopenthixol—Dyspnoea—Hydroxyurea—head and neck cancer	0.00314	0.00537	CcSEcCtD
Zuclopenthixol—Somnolence—Hydroxyurea—head and neck cancer	0.00313	0.00535	CcSEcCtD
Zuclopenthixol—HTR2A—connective tissue—head and neck cancer	0.00313	0.0126	CbGeAlD
Zuclopenthixol—Erythema—Fluorouracil—head and neck cancer	0.00311	0.00531	CcSEcCtD
Zuclopenthixol—Dyspepsia—Hydroxyurea—head and neck cancer	0.0031	0.0053	CcSEcCtD
Zuclopenthixol—ADRA2A—trachea—head and neck cancer	0.00309	0.0124	CbGeAlD
Zuclopenthixol—Decreased appetite—Hydroxyurea—head and neck cancer	0.00306	0.00523	CcSEcCtD
Zuclopenthixol—Pancytopenia—Docetaxel—head and neck cancer	0.00305	0.00522	CcSEcCtD
Zuclopenthixol—Abdominal pain—Vinblastine—head and neck cancer	0.00305	0.00522	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00304	0.0052	CcSEcCtD
Zuclopenthixol—Fatigue—Hydroxyurea—head and neck cancer	0.00304	0.00519	CcSEcCtD
Zuclopenthixol—Pain—Hydroxyurea—head and neck cancer	0.00301	0.00515	CcSEcCtD
Zuclopenthixol—Constipation—Hydroxyurea—head and neck cancer	0.00301	0.00515	CcSEcCtD
Zuclopenthixol—Neutropenia—Docetaxel—head and neck cancer	0.00301	0.00514	CcSEcCtD
Zuclopenthixol—HTR2A—epithelium—head and neck cancer	0.00297	0.0119	CbGeAlD
Zuclopenthixol—Weight increased—Docetaxel—head and neck cancer	0.00293	0.00501	CcSEcCtD
Zuclopenthixol—Vision blurred—Fluorouracil—head and neck cancer	0.00293	0.00501	CcSEcCtD
Zuclopenthixol—Weight decreased—Docetaxel—head and neck cancer	0.00291	0.00498	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Hydroxyurea—head and neck cancer	0.0029	0.00496	CcSEcCtD
Zuclopenthixol—ADRA1A—head—head and neck cancer	0.00285	0.0114	CbGeAlD
Zuclopenthixol—Hypersensitivity—Vinblastine—head and neck cancer	0.00284	0.00486	CcSEcCtD
Zuclopenthixol—Jaundice—Docetaxel—head and neck cancer	0.0028	0.00478	CcSEcCtD
Zuclopenthixol—DRD2—head—head and neck cancer	0.00279	0.0112	CbGeAlD
Zuclopenthixol—Body temperature increased—Hydroxyurea—head and neck cancer	0.00278	0.00476	CcSEcCtD
Zuclopenthixol—Leukopenia—Fluorouracil—head and neck cancer	0.00278	0.00475	CcSEcCtD
Zuclopenthixol—Asthenia—Vinblastine—head and neck cancer	0.00277	0.00474	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00271	0.00464	CcSEcCtD
Zuclopenthixol—Convulsion—Fluorouracil—head and neck cancer	0.00269	0.0046	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Docetaxel—head and neck cancer	0.00268	0.00458	CcSEcCtD
Zuclopenthixol—Myalgia—Fluorouracil—head and neck cancer	0.00264	0.00452	CcSEcCtD
Zuclopenthixol—Diarrhoea—Vinblastine—head and neck cancer	0.00264	0.00452	CcSEcCtD
Zuclopenthixol—HTR2A—trachea—head and neck cancer	0.00262	0.0105	CbGeAlD
Zuclopenthixol—Discomfort—Fluorouracil—head and neck cancer	0.00261	0.00447	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00259	0.00444	CcSEcCtD
Zuclopenthixol—Dizziness—Vinblastine—head and neck cancer	0.00255	0.00437	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Docetaxel—head and neck cancer	0.00254	0.00435	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Docetaxel—head and neck cancer	0.00254	0.00434	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00253	0.00433	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Docetaxel—head and neck cancer	0.00253	0.00433	CcSEcCtD
Zuclopenthixol—Asthenia—Hydroxyurea—head and neck cancer	0.00253	0.00432	CcSEcCtD
Zuclopenthixol—Urethral disorder—Docetaxel—head and neck cancer	0.00252	0.00432	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Fluorouracil—head and neck cancer	0.00249	0.00425	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00248	0.00424	CcSEcCtD
Zuclopenthixol—Visual impairment—Docetaxel—head and neck cancer	0.00248	0.00424	CcSEcCtD
Zuclopenthixol—Tachycardia—Fluorouracil—head and neck cancer	0.00247	0.00423	CcSEcCtD
Zuclopenthixol—Vomiting—Vinblastine—head and neck cancer	0.00245	0.0042	CcSEcCtD
Zuclopenthixol—ADRA2A—thyroid gland—head and neck cancer	0.00244	0.0098	CbGeAlD
Zuclopenthixol—Headache—Vinblastine—head and neck cancer	0.00242	0.00414	CcSEcCtD
Zuclopenthixol—Anorexia—Fluorouracil—head and neck cancer	0.00242	0.00413	CcSEcCtD
Zuclopenthixol—Diarrhoea—Hydroxyurea—head and neck cancer	0.00241	0.00412	CcSEcCtD
Zuclopenthixol—Eye disorder—Docetaxel—head and neck cancer	0.00241	0.00412	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Docetaxel—head and neck cancer	0.00239	0.00409	CcSEcCtD
Zuclopenthixol—Hypotension—Fluorouracil—head and neck cancer	0.00237	0.00405	CcSEcCtD
Zuclopenthixol—Angiopathy—Docetaxel—head and neck cancer	0.00234	0.004	CcSEcCtD
Zuclopenthixol—Dizziness—Hydroxyurea—head and neck cancer	0.00233	0.00398	CcSEcCtD
Zuclopenthixol—Immune system disorder—Docetaxel—head and neck cancer	0.00233	0.00398	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00231	0.00395	CcSEcCtD
Zuclopenthixol—Arrhythmia—Docetaxel—head and neck cancer	0.0023	0.00393	CcSEcCtD
Zuclopenthixol—Nausea—Vinblastine—head and neck cancer	0.00229	0.00392	CcSEcCtD
Zuclopenthixol—Insomnia—Fluorouracil—head and neck cancer	0.00229	0.00392	CcSEcCtD
Zuclopenthixol—Paraesthesia—Fluorouracil—head and neck cancer	0.00228	0.00389	CcSEcCtD
Zuclopenthixol—Dyspnoea—Fluorouracil—head and neck cancer	0.00226	0.00386	CcSEcCtD
Zuclopenthixol—Mental disorder—Docetaxel—head and neck cancer	0.00226	0.00386	CcSEcCtD
Zuclopenthixol—Somnolence—Fluorouracil—head and neck cancer	0.00225	0.00385	CcSEcCtD
Zuclopenthixol—Erythema—Docetaxel—head and neck cancer	0.00224	0.00383	CcSEcCtD
Zuclopenthixol—Malnutrition—Docetaxel—head and neck cancer	0.00224	0.00383	CcSEcCtD
Zuclopenthixol—Vomiting—Hydroxyurea—head and neck cancer	0.00224	0.00383	CcSEcCtD
Zuclopenthixol—Dyspepsia—Fluorouracil—head and neck cancer	0.00223	0.00382	CcSEcCtD
Zuclopenthixol—Rash—Hydroxyurea—head and neck cancer	0.00222	0.0038	CcSEcCtD
Zuclopenthixol—Dermatitis—Hydroxyurea—head and neck cancer	0.00222	0.00379	CcSEcCtD
Zuclopenthixol—Headache—Hydroxyurea—head and neck cancer	0.00221	0.00377	CcSEcCtD
Zuclopenthixol—HRH1—head—head and neck cancer	0.00221	0.00885	CbGeAlD
Zuclopenthixol—Decreased appetite—Fluorouracil—head and neck cancer	0.0022	0.00377	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00219	0.00374	CcSEcCtD
Zuclopenthixol—Pain—Fluorouracil—head and neck cancer	0.00217	0.00371	CcSEcCtD
Zuclopenthixol—ADRA2A—head—head and neck cancer	0.00217	0.0087	CbGeAlD
Zuclopenthixol—Nausea—Hydroxyurea—head and neck cancer	0.00209	0.00358	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Fluorouracil—head and neck cancer	0.00209	0.00357	CcSEcCtD
Zuclopenthixol—Syncope—Docetaxel—head and neck cancer	0.00201	0.00344	CcSEcCtD
Zuclopenthixol—Leukopenia—Docetaxel—head and neck cancer	0.00201	0.00343	CcSEcCtD
Zuclopenthixol—Body temperature increased—Fluorouracil—head and neck cancer	0.002	0.00343	CcSEcCtD
Zuclopenthixol—Palpitations—Docetaxel—head and neck cancer	0.00198	0.00339	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Docetaxel—head and neck cancer	0.00197	0.00337	CcSEcCtD
Zuclopenthixol—Convulsion—Docetaxel—head and neck cancer	0.00194	0.00332	CcSEcCtD
Zuclopenthixol—Hypertension—Docetaxel—head and neck cancer	0.00193	0.00331	CcSEcCtD
Zuclopenthixol—Myalgia—Docetaxel—head and neck cancer	0.00191	0.00326	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00189	0.00324	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Fluorouracil—head and neck cancer	0.00187	0.00319	CcSEcCtD
Zuclopenthixol—Dry mouth—Docetaxel—head and neck cancer	0.00187	0.00319	CcSEcCtD
Zuclopenthixol—HTR2A—head—head and neck cancer	0.00184	0.00739	CbGeAlD
Zuclopenthixol—Anaphylactic shock—Docetaxel—head and neck cancer	0.00183	0.00313	CcSEcCtD
Zuclopenthixol—Shock—Docetaxel—head and neck cancer	0.0018	0.00308	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Docetaxel—head and neck cancer	0.00179	0.00307	CcSEcCtD
Zuclopenthixol—Pruritus—Fluorouracil—head and neck cancer	0.00179	0.00307	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Docetaxel—head and neck cancer	0.00179	0.00306	CcSEcCtD
Zuclopenthixol—Tachycardia—Docetaxel—head and neck cancer	0.00179	0.00305	CcSEcCtD
Zuclopenthixol—Skin disorder—Docetaxel—head and neck cancer	0.00178	0.00304	CcSEcCtD
Zuclopenthixol—Anorexia—Docetaxel—head and neck cancer	0.00174	0.00298	CcSEcCtD
Zuclopenthixol—Diarrhoea—Fluorouracil—head and neck cancer	0.00173	0.00297	CcSEcCtD
Zuclopenthixol—Hypotension—Docetaxel—head and neck cancer	0.00171	0.00292	CcSEcCtD
Zuclopenthixol—CYP2D6—head—head and neck cancer	0.00168	0.00674	CbGeAlD
Zuclopenthixol—Dizziness—Fluorouracil—head and neck cancer	0.00168	0.00287	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00167	0.00285	CcSEcCtD
Zuclopenthixol—Insomnia—Docetaxel—head and neck cancer	0.00165	0.00283	CcSEcCtD
Zuclopenthixol—Paraesthesia—Docetaxel—head and neck cancer	0.00164	0.00281	CcSEcCtD
Zuclopenthixol—Dyspnoea—Docetaxel—head and neck cancer	0.00163	0.00279	CcSEcCtD
Zuclopenthixol—Somnolence—Docetaxel—head and neck cancer	0.00163	0.00278	CcSEcCtD
Zuclopenthixol—Vomiting—Fluorouracil—head and neck cancer	0.00161	0.00276	CcSEcCtD
Zuclopenthixol—Dyspepsia—Docetaxel—head and neck cancer	0.00161	0.00275	CcSEcCtD
Zuclopenthixol—Rash—Fluorouracil—head and neck cancer	0.0016	0.00273	CcSEcCtD
Zuclopenthixol—Dermatitis—Fluorouracil—head and neck cancer	0.0016	0.00273	CcSEcCtD
Zuclopenthixol—Decreased appetite—Docetaxel—head and neck cancer	0.00159	0.00272	CcSEcCtD
Zuclopenthixol—Headache—Fluorouracil—head and neck cancer	0.00159	0.00272	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00158	0.0027	CcSEcCtD
Zuclopenthixol—Fatigue—Docetaxel—head and neck cancer	0.00158	0.0027	CcSEcCtD
Zuclopenthixol—Pain—Docetaxel—head and neck cancer	0.00156	0.00268	CcSEcCtD
Zuclopenthixol—Constipation—Docetaxel—head and neck cancer	0.00156	0.00268	CcSEcCtD
Zuclopenthixol—HRH1—lymph node—head and neck cancer	0.00154	0.0062	CbGeAlD
Zuclopenthixol—ADRA2A—lymph node—head and neck cancer	0.00152	0.00609	CbGeAlD
Zuclopenthixol—Feeling abnormal—Docetaxel—head and neck cancer	0.00151	0.00258	CcSEcCtD
Zuclopenthixol—Nausea—Fluorouracil—head and neck cancer	0.00151	0.00257	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Docetaxel—head and neck cancer	0.0015	0.00256	CcSEcCtD
Zuclopenthixol—Abdominal pain—Docetaxel—head and neck cancer	0.00145	0.00247	CcSEcCtD
Zuclopenthixol—Body temperature increased—Docetaxel—head and neck cancer	0.00145	0.00247	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Docetaxel—head and neck cancer	0.00135	0.0023	CcSEcCtD
Zuclopenthixol—Asthenia—Docetaxel—head and neck cancer	0.00131	0.00224	CcSEcCtD
Zuclopenthixol—Pruritus—Docetaxel—head and neck cancer	0.00129	0.00221	CcSEcCtD
Zuclopenthixol—Diarrhoea—Docetaxel—head and neck cancer	0.00125	0.00214	CcSEcCtD
Zuclopenthixol—Dizziness—Docetaxel—head and neck cancer	0.00121	0.00207	CcSEcCtD
Zuclopenthixol—Vomiting—Docetaxel—head and neck cancer	0.00116	0.00199	CcSEcCtD
Zuclopenthixol—Rash—Docetaxel—head and neck cancer	0.00115	0.00197	CcSEcCtD
Zuclopenthixol—Dermatitis—Docetaxel—head and neck cancer	0.00115	0.00197	CcSEcCtD
Zuclopenthixol—Headache—Docetaxel—head and neck cancer	0.00115	0.00196	CcSEcCtD
Zuclopenthixol—Nausea—Docetaxel—head and neck cancer	0.00109	0.00186	CcSEcCtD
